A Study to Evaluate INCA033989 Administered as a Monotherapy or in Combination With Ruxolitinib in Participants With Myeloproliferative Neoplasms
Conditions
Myeloproliferative Neoplasms
Simple summaryAI-assisted
This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.
Locations
City of Hope Medical Center, Duarte, California, United States
Stanford Cancer Institute, Palo Alto, California, United States
University of Miami Health System, Miami, Florida, United States
The University of Kansas Cancer Center, Westwood, Kansas, United States
Johns Hopkins Hospital, Baltimore, Maryland, United States
Dana Farber Cancer Institute, Boston, Massachusetts, United States
Washington University School of Medicine, St Louis, Missouri, United States
Icahn School of Medicine At Mount Sinai, New York, New York, United States
Memorial Sloan Kettering Cancer Center, New York, New York, United States
Wake Forest Baptist Medical Center, Winston-Salem, North Carolina, United States
Cleveland Clinic, Cleveland, Ohio, United States
Vanderbilt University Medical Center, Nashville, Tennessee, United States
Md Anderson Cancer Center, Houston, Texas, United States
Study leads
Incyte Medical Monitor
Study Director
Incyte Corporation